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We thank our colleagues Cheng and
associates for their commentary with
regard to our recently published article,
‘‘The Sentinel Node Concept in Ade-
nocarcinomas of the Distal Esophagus
and Gastroesophageal Junction.’’1 In
this study, we used the widely recog-
nized immunohistochemical assay in
which antibodies against epithelial-
cell proteins are used to detect small
clusters of tumor cells in histologically
node-negative lymph nodes of patients
with esophageal adenocarcinoma. Yao
and Han claim that the monoclonal an-
tibody against cytokeratin 8 and 18
(clone NCL-5D3) that we used in the
present study should not be mistaken
with the CAM5.2 antibody (clone
CAM5.2) that appears to be specific
for cytokeratin 7 and 8. In our article,
we stated that the used antibody
CAM 5.2 is specific for intracellular
cytokeratin 8 and 18, referring to the
original paper of Makin, Bobrow, and
Bodmer,2 in which it is claimed that
(at that time newly developed)
antibody CAM5.2 identifies the lower
molecular weight cytokeratins (cyto-
keratin 8, 18 and 19). Other studies
that investigated the presence and
relevance of micrometastases or iso-
lated tumor cells by using antibody
CAM5.2 have also referred to this arti-
cle.3 However, over the last years,
companies producing these antibodiesThe Journalhave changed their products and fur-
ther investigated the corresponding
specificity in reactivity against certain
cytokeratins, as pointed out by Yao
and Han. Therefore, their statement
that antibody CAM5.2 is not specific
for intracellular cytokeratin 8 and 18
is correct. Nevertheless, this finding
does not affect the conclusions of our
study. The presence of cytokeratin 8
and/or 18 (which are both expressed
in esophageal adenocarcinoma4) as
detected with the antibody used in
our study (clone NCL-5D3) indicates
epithelial cell deposits in lymphoid
tissue. Therefore, these cytokeratin
deposits will still imply the presence
of micrometastatic disease.
Brechtje A. Grotenhuis
Bas P. L. Wijnhoven
Herman van Dekken
J. Jan B. van Lanschot
Erasmus Medical Center
Rotterdam, The Netherlands
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To the Editor:
We read with great interest the arti-
cle by Atluri and colleagues,1 and weof Thoracic and Cardiovascular Surgercongratulate them for their experi-
ments with myocardial perfusion and
contractility improvement using a laser
transmyocardial approach. We agree
with the authors that the problem
with myocardial revascularization in
patients who might not benefit from
conventional procedures still demands
investigative efforts. This was the gen-
esis of a research program we began at
Laval University in Quebec and that
we are going to start in Europe at Uni-
versite´ Paris Sud. This program is
aimed at the enhancement of noncoro-
nary collateral circulation (NCCC).
Our animal models are dogs (Canada)
and pigs (France).
NCCC is a topic that is virtually ig-
nored,with very fewpublications in ex-
istence. This is surprising, considering
that it is not rare to find evidence of
NCCC, such as during coronary bypass
surgerywhen arterial blood flowcomes
from the coronary ostia during valve re-
placement surgery or from the incised
coronary artery, despite adequate aortic
crossclamping and venting. NCCC
consists of a network of small channels
that come from mediastinal, bronchial,
and pericardial vessels and that enter
the heart through the pericardial reflec-
tions surrounding the pulmonary and
systemic veins, as well as through the
vasa vasorum of the aorta and pulmo-
nary artery leading to and from the
myocardium. Our studies are premised
on the belief that this network is bigger
than generally thought and that it might
play a role, if adequately enhanced, as
an alternative means of myocardial
blood supply. We also believe that the
normal ventricular function sometimes
seen in patients with occlusion of the 3
major coronary vessels can be evidence
of myocardial nourishment related to
such a collateral source. Previous stud-
ies2 have shown that vascular connec-
tions exist between the internal
thoracic arteries (ITAs) and myocar-
dium and that surgical bilateral ligation
of the ITAs creates a local hypertensive
status, increasing the perfusion pres-
sure within the channels leading to the
heart.3y c Volume 139, Number 6 1675
